Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Viatris Inc.
  6. Summary
    VTRS   US92556V1061

VIATRIS INC.

(VTRS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
13.57(c) 13.99(c) 14.01(c) 13.94(c) 13.8 Last
4 969 623 7 193 473 4 165 570 3 719 579 10 332 585 Volume
+0.59% +3.10% +0.14% -0.50% -1.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 17 803 M - -
Net income 2021 -1 188 M - -
Net Debt 2021 22 703 M - -
P/E ratio 2021 -8,95x
Yield 2021 2,38%
Sales 2022 17 625 M - -
Net income 2022 1 546 M - -
Net Debt 2022 19 706 M - -
P/E ratio 2022 146x
Yield 2022 4,28%
Capitalization 16 688 M 16 688 M -
EV / Sales 2021 2,21x
EV / Sales 2022 2,06x
Nbr of Employees 40 000
Free-Float 99,7%
More Financials
Company
Viatris Inc. (Viatris) is a healthcare company. The Company operates through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan, and Hong Kong. The JANZ segment includes its operations in Japan, Australia, and New Zealand. The... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Ratings of Viatris Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about VIATRIS INC.
10/21BIOCON : Biologics First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed wi..
AQ
10/20VIATRIS' : Semglee Insulin Injection to be Listed on Express Scripts' National Preferred F..
MT
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/13VIATRIS INC. : to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
PR
10/12VIATRIS : Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Scler..
AQ
10/11VIATRIS : Named Fifth on Fortune's Change the World List
PR
10/03PFIZER : to Transfer Upjohn Business to India's Mylan for $24 Million
MT
09/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Via..
BU
09/17VIATRIS : Former Mylan executive pleads guilty to insider trading
RE
09/03JOHNSON & JOHNSON : Lifesaving TB Medicines Still Out of Reach for Children in High-Burden..
AQ
08/30VIATRIS INC. : to Participate in Citi's 16th Annual BioPharma Conference
PR
08/30VIATRIS INC. : to Participate in BofA Global Healthcare Conference
PR
08/23VIATRIS INC. : Ex-dividend day for
FA
08/11VIATRIS : Plant owner in talks with WVU to transfer shuttered facility
AQ
08/09VIATRIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA..
AQ
More news
News in other languages on VIATRIS INC.
10/20L'insuline injectable Semglee de Viatris sera inscrite sur la liste des médicaments pré..
10/03Pfizer transfère l'activité d'Upjohn à la société indienne Mylan pour 24 millions de do..
07/06Les entreprises américaines générant le plus de chiffre d’affaires
03/03ASTRAZENECA : victoire judiciaire face à Mylan et Kindeva
02/02Le vaccin anti-Covid va générer 15 milliards de dollars de revenus à Pfizer
More news
Analyst Recommendations on VIATRIS INC.
More recommendations
Chart VIATRIS INC.
Duration : Period :
Viatris Inc. Technical Analysis Chart | VTRS | US92556V1061 | MarketScreener
Technical analysis trends VIATRIS INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 13,80 $
Average target price 19,29 $
Spread / Average Target 39,8%
EPS Revisions
Managers and Directors
Michael Goettler Chief Executive Officer & Director
Rajiv Malik President & Director
Sanjeev Narula Chief Financial Officer
Robert J. Coury Executive Chairman
Ramkumar V. Rayapureddy Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
VIATRIS INC.-26.36%16 858
JOHNSON & JOHNSON4.26%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY45.14%220 979